A Brief Review on Medicinal Plants-At-Arms against COVID-19

Figure 2

Schematic representation of registered clinical trials for COVID-19 on drug supplements, herbal and botanicals, and plant-derived secondary metabolites. Data collected from two registry platforms (ClinicalTrials.gov and ICTRP). (a) Bar chart representing number of clinical trials registered in ClinicalTrials.gov and ICTRP for vitamins, minerals, herbal and botanicals, secondary metabolites, and amino acids, (b) pie chart showing analysis of data collected from ICTRP on the percentage share of Ayurveda (39%), traditional Chinese medicine (29%), dietary supplements (19%), herbal and botanicals (11%), secondary metabolites (2%), and Unani medicine (0.29%) in registered clinical studies apart from vaccines. Doughnut representation showing individual category on (c) amino acids, (d) herbal/botanical, (e) secondary metabolites, (f) vitamins, and (g) minerals registered for clinical trials at ClinicalTrials.gov (inner doughnut) and ICTRP (outer doughnut).

(a)

(b)

(c)

(d)

(e)

(f)

(g)